The interleukin-2: Interleukin-2 receptor interaction has been one of the most intensely investigated ligand receptor system of the hematopoietic/lymphokine family. Recent findings demonstrate that is system remains an enigma in many respects. Not only is the biochemical mechanism of signal transduction unknown, but within the last year the longstanding 3 dimensional structure for IL-2 has been shown to be incorrect and a third cell surface receptor subunit has been identified. The presence of three cell surface subunits (p55, p64 and p75) makes this receptor system unique among the expanding family of hematopoietic receptors. The knowledge of how each subunit functions with respect to ligand capture, signal transmission and in internalization is essential for the development of ligand based IL-2 agonists and antagonists. We and others have demonstrated that these subunits must function as heterodimers on the cell surface. Only one of the subunits (p55) is capable of interacting with ligand in solution in a manner that resembles cell surface binding. The long term goal of this project is to engineer soluble IL-2 receptor ectodomains that associate in a directed multimeric fashion in solution by exploiting the wealth of knowledge concerning the specificity and stability of coiled - coil (Leu Zipper) molecular recognition.
The Specific Aims of this project are: A. To engineer and express fusion proteins that combine each receptor ectodomain with coiled- coil recognition sequences designed to specifically direct subunit interaction in solution. B. To characterize receptor subunit complexation using biophysical methods. C. To quantitate the ligand binding properties of the soluble receptor complexes and compare them to the equivalent cell surface structures. D. To optimize the designs of the soluble complexes such that bind ligand will greatly facilitate the characterization of this ligand receptor system. In addition, these results will demonstrate the feasibility of this approach for the study of other members of the hematopoietic receptor family.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI034331-02
Application #
2069449
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1994-05-01
Project End
1998-01-31
Budget Start
1995-02-01
Budget End
1996-01-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Cullen, Paul A; Haake, David A; Adler, Ben (2004) Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev 28:291-318
Liparoto, Stefano F; Myszka, David G; Wu, Zining et al. (2002) Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding. Biochemistry 41:2543-51
Liparoto, S F; Ciardelli, T L (1999) Biosensor analysis of the interleukin-2 receptor complex. J Mol Recognit 12:316-21
Wu, Z; Goldstein, B; Laue, T M et al. (1999) Solution assembly of the pseudo-high affinity and intermediate affinity interleukin-2 receptor complexes. Protein Sci 8:482-9
Wang, R; Ciardelli, T L; Russell, J H (1997) Partial signaling by cytokines: cytokine regulation of cell cycle and Fas-dependent, activation-induced death in CD4+ subsets. Cell Immunol 182:152-60
Myszka, D G; Arulanantham, P R; Sana, T et al. (1996) Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. Protein Sci 5:2468-78
Wu, Z; Johnson, K W; Choi, Y et al. (1995) Ligand binding analysis of soluble interleukin-2 receptor complexes by surface plasmon resonance. J Biol Chem 270:16045-51
Wu, Z; Johnson, K W; Goldstein, B et al. (1995) Solution assembly of a soluble, heteromeric, high affinity interleukin-2 receptor complex. J Biol Chem 270:16039-44
Nakarai, T; Robertson, M J; Streuli, M et al. (1994) Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med 180:241-51